The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

The late-stage trial will recruit about 25,000 people around the world to test the new vaccine from Moderna.View on euronews ...

As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden.

The winter vomiting bug affects millions of Britons every year, but a new vaccine could help reduce the massive impact of ...

The trial will evaluate the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403 ...

The first, an investigational norovirus mRNA vaccine from Moderna (mRNA-1403), safely elicited strong antibody responses in ...

There are currently no licensed vaccines to treat norovirus, a highly contagious virus that causes sickness and diarrhoea.

The first phase 3 randomised clinical trial of an investigational mRNA norovirus vaccine will open across the UK within the next two weeks. Sponsored by Moderna, the trial evaluates the efficacy and ...

A new vaccine that could stop people from developing the vomiting bug norovirus is on trial in the UK. The mRNA vaccine from ...

A vaccine to protect against the winter vomiting bug norovirus is set for a year-long trial by the UK’s National Health Service (NHS) after early results showed it creates a “strong immune response.” ...

Experts hope the Moderna jab could stop people developing the vomiting and diarrhoea bug, which is linked to around 12,000 ...